Treatment Study for Patients with Newly Diagnosed B-Lymphoblastic Leukemia or B-Lineage Lymphoblastic Lymphoma
To determine if a maintenance regimen containing weekly oral methotrexate at 40mg/m2/week will result in an improved disease free survival (DFS) compared to that containing weekly oral methotrexate at 20mg/m2/week in the average risk subset of patients with standard risk B-ALL.
In order to participate you must meet the following criteria:
- Have newly diagnosed NCI standard risk B-ALL or B-LLy Murphy Stages I or II.
- Have an initial white blood cell count < 50,000/uL.
This is a partial list of elgibility requirements.